

Vicore Pharma to Participate in Upcoming Healthcare Conferences

Stockholm, Sweden & Cambridge, Mass., September 1, 2026 – Vicore Pharma Holding AB (Nasdaq Stockholm: VICO, Nasdaq US: VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAgS), today announced that the company will participate in the following upcoming healthcare conferences:

- **Wells Fargo Healthcare Conference**

Location: Encore Boston Harbor, Boston, Mass.

Format: 1×1 meetings

Participation Date: Tuesday, September 8, 2026

Participant: Ahmed Mousa, Chief Executive Officer

- **Cantor Global Healthcare Conference**

Location: Waldorf Astoria New York, New York, N.Y.

Format: Fireside chat and 1×1 meetings

Fireside Chat Date and Time: Friday, September 11, 2026, 9:45–10:15 AM ET

Webcast: [Link](#)

Participant: Ahmed Mousa, Chief Executive Officer

For more information, please contact:

Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma

Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

Attachments

[Vicore Pharma to Participate in Upcoming Healthcare Conferences](#)